Haemonetics Corporation (HAE)

Name: Haemonetics Corporation Financial Statements
Creator: Quarter Results

Healthcare | Medical Instruments Supplies

Latest reporting period: 2025-12-27

Latest Quarter

2025-12-27

Revenue

$339M

Net Income

$44.7M

Operating Margin

20.5%

Free Cash Flow

$142M

Debt / Assets

66.5%

Values are in USD and rounded to the nearest whole number unless noted.

Swipe horizontally to view all columns.

Income statement quarterly history for Haemonetics Corporation (HAE).
Income Statement (Quarterly)	2025-12-27	2025-09-27	2025-06-28	2025-03-29
Revenue	338,967,000	327,315,000	321,394,000	330,599,000
Cost of Revenue	136,581,000	132,571,000	129,535,000	137,549,000
Gross Profit	202,386,000	194,744,000	191,859,000	193,050,000
Operating Expenses
R&D Expenses	0	0	0	0
SG&A Expenses	109,154,000	101,615,000	0	115,360,000
Operating Expenses	134,990,000	136,253,000	137,987,000	131,274,000
Operating Income	69,560,000	58,491,000	53,872,000	71,335,000
Interest Expense	8,122,000	7,212,000	4,073,000	-598,000
Income Before Tax	59,975,000	51,285,000	45,169,000	70,737,000
Income Tax Expense	15,235,000	12,601,000	11,138,000	12,756,000
Net Income	44,740,000	38,684,000	34,031,000	57,981,000
Per Share
EPS	0.96	0.81	0.71	1.17
EPS Diluted	0.00	0.00	0.00	0.00

Income statement annual history for Haemonetics Corporation (HAE).
Income Statement (Annual)	2025-03-31	2025-03-29	2024-03-30	2023-04-01	2023-03-31
Revenue	1,360,824,000	1,360,824,000	1,309,055,000	1,168,660,000	1,168,660,000
Cost of Revenue	611,866,000	582,278,000	617,507,000	553,563,000	553,563,000
Gross Profit	748,958,000	778,546,000	691,548,000	615,097,000	615,097,000
Operating Expenses
R&D Expenses	0	0	0	0	0
SG&A Expenses	436,789,000	422,051,000	431,780,000	376,675,000	376,675,000
Operating Expenses	527,141,000	556,729,000	526,665,000	459,064,000	459,064,000
Operating Income	221,817,000	221,817,000	164,883,000	156,033,000	156,033,000
Interest Expense	9,746,000	9,746,000	13,018,000	14,630,000	14,630,000
Income Before Tax	212,071,000	212,071,000	151,865,000	141,403,000	141,403,000
Income Tax Expense	44,392,000	44,392,000	34,307,000	26,002,000	26,002,000
Net Income	167,679,000	167,679,000	117,558,000	115,401,000	115,401,000
Per Share
EPS	3.31	3.31	2.32	2.27	0.00
EPS Diluted	0.00	0.00	0.00	0.00	0.00

Balance sheet quarterly history for Haemonetics Corporation (HAE).
Balance Sheet (Quarterly)	2025-03-31	2025-03-29	2024-03-31	2024-03-30
Assets
Cash and Cash Equivalents	306,763,000	306,763,000	178,800,000	178,800,000
Short Term Investments	0	0	0	0
Net Receivables	202,657,000	202,657,000	206,562,000	206,562,000
Inventory	365,141,000	365,141,000	317,202,000	317,202,000
Total Current Assets	934,975,000	934,975,000	768,903,000	768,903,000
Property Plant Equipment	284,052,000	284,052,000	311,362,000	366,630,000
Goodwill and Intangibles	1,060,011,000	1,060,011,000	971,199,000	971,199,000
Total Assets	2,450,948,000	2,450,948,000	2,195,591,000	2,195,591,000
Liabilities
Account Payables	66,999,000	66,999,000	0	73,358,000
Short Term Debt	303,558,000	303,558,000	10,229,000	10,229,000
Total Current Liabilities	578,113,000	578,113,000	300,383,000	300,383,000
Long Term Debt	921,230,000	921,230,000	797,564,000	797,564,000
Total Liabilities	1,630,112,000	1,630,112,000	1,235,632,000	1,235,632,000
Shareholders Equity
Retained Earnings	352,174,000	352,174,000	0	360,456,000
Total Shareholders Equity	820,836,000	820,836,000	959,959,000	959,959,000

Balance sheet annual history for Haemonetics Corporation (HAE).
Balance Sheet (Annual)	2025-03-31	2025-03-29	2024-03-31	2024-03-30	2023-04-01
Assets
Cash and Cash Equivalents	306,763,000	306,763,000	178,800,000	178,800,000	284,466,000
Short Term Investments	0	0	0	0	1,110,000
Net Receivables	202,657,000	202,657,000	206,562,000	206,562,000	179,142,000
Inventory	365,141,000	365,141,000	317,202,000	317,202,000	259,379,000
Total Current Assets	934,975,000	934,975,000	768,903,000	768,903,000	769,722,000
Property Plant Equipment	284,052,000	284,052,000	311,362,000	366,630,000	310,885,000
Goodwill and Intangibles	1,060,011,000	1,060,011,000	971,199,000	971,199,000	742,002,000
Total Assets	2,450,948,000	2,450,948,000	2,195,591,000	2,195,591,000	1,934,825,000
Liabilities
Account Payables	66,999,000	66,999,000	0	73,358,000	63,929,000
Short Term Debt	303,558,000	303,558,000	10,229,000	10,229,000	11,784,000
Total Current Liabilities	578,113,000	578,113,000	300,383,000	300,383,000	251,816,000
Long Term Debt	921,230,000	921,230,000	797,564,000	797,564,000	754,102,000
Total Liabilities	1,630,112,000	1,630,112,000	1,235,632,000	1,235,632,000	1,116,828,000
Shareholders Equity
Retained Earnings	352,174,000	352,174,000	0	360,456,000	253,168,000
Total Shareholders Equity	820,836,000	820,836,000	959,959,000	959,959,000	817,997,000

Cash flow quarterly history for Haemonetics Corporation (HAE).
Cash Flow Statement (Quarterly)	2025-03-31	2025-03-29	2024-03-30	2023-04-01
Operating Activities
Net Income	167,679,000	167,679,000	117,558,000	115,401,000
Depreciation & Amortization	115,586,000	115,586,000	97,215,000	93,307,000
Stock Based Compensation	29,636,000	29,636,000	28,332,000	25,583,000
Change in Working Capital	-101,962,000	-101,962,000	-74,701,000	25,503,000
Operating Cash Flow	181,725,000	181,725,000	181,751,000	273,058,000
Investing Activities
Capital Expenditure	-39,278,000	-39,278,000	-66,296,000	-110,191,000
Investments	-39,278,000	-39,278,000	-66,296,000	-110,191,000
Investing Cash Flow	-161,895,000	-161,895,000	-322,389,000	-143,788,000
Financing Activities
Debt Repayment	447,312,000	447,312,000	37,750,000	-9,625,000
Common Stock Issued/Repurchased	-225,000,000	-225,000,000	0	-67,984,000
Dividends Paid	0	0	0	0
Financing Cash Flow	108,818,000	108,818,000	38,157,000	-100,364,000
Summary
Free Cash Flow	142,447,000	142,447,000	115,455,000	162,867,000
Net Change in Cash	127,963,000	127,963,000	-105,666,000	24,970,000

Cash flow annual history for Haemonetics Corporation (HAE).
Cash Flow Statement (Annual)	2025-03-31	2025-03-29	2024-03-30	2023-04-01	2023-03-31
Operating Activities
Net Income	167,679,000	167,679,000	117,558,000	115,401,000	115,401,000
Depreciation & Amortization	115,586,000	115,586,000	97,215,000	93,307,000	93,307,000
Stock Based Compensation	29,636,000	29,636,000	28,332,000	25,583,000	25,583,000
Change in Working Capital	-101,962,000	-101,962,000	-74,701,000	25,503,000	25,503,000
Operating Cash Flow	181,725,000	181,725,000	181,751,000	273,058,000	273,058,000
Investing Activities
Capital Expenditure	-39,278,000	-39,278,000	-66,296,000	-110,191,000	-110,191,000
Investments	-39,278,000	-39,278,000	-66,296,000	-110,191,000	-110,191,000
Investing Cash Flow	-161,895,000	-161,895,000	-322,389,000	-143,788,000	-143,788,000
Financing Activities
Debt Repayment	447,312,000	447,312,000	37,750,000	-9,625,000	-9,625,000
Common Stock Issued/Repurchased	-225,000,000	-225,000,000	0	-67,984,000	-75,000,000
Dividends Paid	0	0	0	0	0
Financing Cash Flow	108,818,000	108,818,000	38,157,000	-100,364,000	-100,364,000
Summary
Free Cash Flow	142,447,000	142,447,000	115,455,000	162,867,000	162,867,000
Net Change in Cash	127,963,000	127,963,000	-105,666,000	24,970,000	24,970,000